Highest-materiality recent filing
InspireMD Q1 revenue $3.4M (+122% YoY); voluntary recall of CGuard Prime 135 cm
Net loss $13.7M ($0.16/share) vs $11.2M loss a year ago; operating expenses rose to $14.7M.
Voluntary recall of CGuard Prime 135 cm delivery system in US; technical success not met. No safety issues for implanted stent.
InspireMD enters $75M ATM equity facility with BTIG; terminates prior Piper Sandler ATM
Entered Equity Distribution Agreement with BTIG to sell up to $75M of common stock via ATM offering.
InspireMD reports Q4 revenue $3.1M (+62% YoY); guides FY2026 rev $13-15M
Q4 revenue $3.1M, up 62% YoY; U.S. rev $0.9M (sequential +74%)
InspireMD dismisses COO Andrea Tommasoli effective April 1, 2026
Andrea Tommasoli, COO, given notice of dismissal on February 27, 2026.
InspireMD director Kathryn Arnold resigns; company awards ~$140k in accelerated equity and fees
Kathryn Arnold, Class III director, resigns effective Dec 31, 2025; no disagreement with company.
InspireMD Q3 revenue record $2.5M (+39% YoY) as U.S. CGuard Prime launch gains traction
U.S. revenue of $497k marks first commercial quarter for CGuard Prime carotid stent system.
InspireMD Appoints Dan Dearen to Board, Replacing Thomas Kester
Thomas Kester resigned as Class III director effective Sept. 16, 2025; no disagreement cited.
InspireMD appoints Raymond Cohen to Audit and Compensation Committees
Raymond W. Cohen appointed to Audit Committee and Compensation Committee on September 7, 2025.
InspireMD Q2 net loss widens to $13.2M ($0.26/share); revenue up 2.3% to $1.78M
Net loss of $13.2M ($0.26 per share) vs $7.9M loss ($0.22) in Q2 2024; operating expenses surged 55% to $13.3M.
InspireMD raises $58M via PIPE and warrant exercise; appoints Ray Cohen to board
PIPE gross proceeds $40.1M: 16.6M shares/pre-funded warrants at $2.42/share; led by OrbiMed and Marshall Wace.
InspireMD launches CGuard Prime carotid stent system in US after FDA PMA approval
U.S. commercial launch of CGuard Prime carotid stent system after FDA PMA approval.
FDA approved CGuard Prime carotid stent system on June 23, 2025 for stroke prevention in carotid artery stenosis.
InspireMD receives CE Mark approval for CGuard Prime EPS under EU MDR
CE Mark approval under European Medical Device Regulation (MDR) for CGuard Prime Embolic Prevention System.
InspireMD shareholders re-elect Berman and Ward, ratify auditors at 2025 annual meeting
Directors Berman and Ward re-elected as Class 2 directors: Berman 12,429,779 for, 248,915 withheld; Ward 12,447,235 for, 231,459 withheld; 7,800,113 broker non-votes each.
InspireMD appoints Michael Lawless as CFO, succeeding Craig Shore
Michael Lawless appointed CFO effective on/before June 30, 2025; succeeds Craig Shore who served ~15 years.
On June 2, 2025, InspireMD, Inc. (the “ Company ”) appointed Michael Lawless as Chief Financial Officer of the Company, effective on or before June 30, 2025 (the “ Effective Date ”).
On the Effective Date, Mr. Lawless will succeed Craig Shore, whose employment as the Company’s Chief Financial Officer will be terminated simultaneous with Mr. Lawless’s appointment.
Max materiality 0.90 · Median 0.68 · Most common event earnings